Xin Lang Cai Jing·2026-03-31 14:55Summary of Key Points Core Viewpoint - The latest executive compensation data for Shanghai Pharmaceuticals reveals a significant decrease in total compensation for directors and senior management over the past three years, alongside a modest increase in stock price from 2023 to 2025 [1][3]. Group 1: Executive Compensation - Shanghai Pharmaceuticals has a total of 12 directors and senior management, with an average age of 53 years and a median age of 54 years [1][6]. - The total compensation for directors and senior management in 2025 is 19.61 million yuan, with an average salary of 2.59 million yuan and a median salary of 2.55 million yuan [1][6]. - The highest-paid executive is CEO Li Yongzhong, earning 3.32 million yuan, while the lowest-paid is Vice President Shao Shuai, earning 1.89 million yuan [1][6]. Group 2: Yearly Compensation Trends - The total compensation for directors and senior management has decreased from 42.19 million yuan in 2023 to 17.06 million yuan in 2024, and then to 19.61 million yuan in 2025, representing a total decrease of 22.58 million yuan, or 53.52% from 2023 to 2025 [3][8]. - The compensation for individual executives varies, with some experiencing significant increases or decreases compared to the previous year [2][7]. Group 3: Stock Price Performance - The stock price of Shanghai Pharmaceuticals increased from 15.96 yuan at the end of 2023 to 17.74 yuan at the end of 2025, reflecting an increase of 11.12% [9]. - The annual stock price fluctuations show a decline of 13.65% in 2025, following an increase of 28.68% in 2024 and a decrease of 3.34% in 2023 [10].